Figure 1.
Survival outcomes and mutational landscape of pAML vs sAML. (A-C) Kaplan-Meier survival curves of pAML vs sAML (A), NK-pAML vs NK-sAML (B), and AK-pAML vs AK-sAML (C). (D) Bar graph showing the frequency (percentage) of somatic mutations in pAML vs sAML. (E-F) Forest plots representing univariate logistic regression and MLR analyses showing the odds ratio (OR; in log scale) of the association of somatic mutations in pAML vs sAML, respectively. (G) Forest plots representing univariate analyses showing the OR (in log scale) of the association of dominant/ancestral and secondary/subclonal somatic mutations in pAML vs sAML, respectively. Levels of statistical significance, indicated by green, orange, and black (P < .0001, P < .05, and P > .05, respectively), were obtained by Fisher’s exact test. (H) Bar graph showing the average predictive performance (∽0.74) of MLR using cross-validation area under the curve (ie, we correctly predicted pAML and sAML classification in ∼74% of AML cases in our cohort using the distinct genomic characteristics of each subtype). ns, not significant.

Survival outcomes and mutational landscape of pAML vs sAML. (A-C) Kaplan-Meier survival curves of pAML vs sAML (A), NK-pAML vs NK-sAML (B), and AK-pAML vs AK-sAML (C). (D) Bar graph showing the frequency (percentage) of somatic mutations in pAML vs sAML. (E-F) Forest plots representing univariate logistic regression and MLR analyses showing the odds ratio (OR; in log scale) of the association of somatic mutations in pAML vs sAML, respectively. (G) Forest plots representing univariate analyses showing the OR (in log scale) of the association of dominant/ancestral and secondary/subclonal somatic mutations in pAML vs sAML, respectively. Levels of statistical significance, indicated by green, orange, and black (P < .0001, P < .05, and P > .05, respectively), were obtained by Fisher’s exact test. (H) Bar graph showing the average predictive performance (∽0.74) of MLR using cross-validation area under the curve (ie, we correctly predicted pAML and sAML classification in ∼74% of AML cases in our cohort using the distinct genomic characteristics of each subtype). ns, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal